Cell Counting Kit‐8 (CCK‐8) assays were performed to assess the proliferative capacity of lenvatinib‐resistant HCC cells with HECTD2 knockdown and lenvatinib‐sensitive cells with HECTD2 overexpression. Here, HECTD2 is linked to hepatocellular carcinoma.